Zortress /Everolimus

PreclinicalSmall molecule

UUniversity of Kentucky

Zortress /Everolimus is one of 29 small molecule programs targeting Calcification. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CalcificationActive, not recruiting

CalcificationPreclinical

Active, not recruiting

Competition

Competitive Landscape

46 competitors in Calcification

#DrugCompanyPhaseTrials

Rocaltrol

Alnylam Pharmaceuticals

Approved

1 2

Eliquis

Bristol-Myers Squibb

Approved

1 3

Zemplar

AbbVie

Approved

1 4

Xarelto

WWim Janssens

Approved

3 5

Coumadin

AAbbott

Approved

2 6

Fosamax

OOrganon and Co

Approved

2 7

Circadin

NNeurim Pharmaceuticals Ltd.

Approved

1 8

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 9

Farxiga

AstraZeneca

Phase 3

1 10

Aldactone

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Calcification1 trial

Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients

Withdrawn·UUniversity of Kentucky·N/A·NCT01612299

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Zortress /Everolimus. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zortress /Everolimus compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zortress /Everolimus. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Kentucky company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Kentucky

Zortress /Everolimus

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Calcification1 trial

References

Drug Info

Quick Facts

Related News